搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Laribacter hongkongensis tRNA modification GTPase MnmE (mnmE) CSB-YP509030LNO
CSB-EP509030LNO
CSB-BP509030LNO
CSB-MP509030LNO
CSB-EP509030LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Chromosomal replication initiator protein DnaA (dnaA) CSB-YP509031LNO
CSB-EP509031LNO
CSB-BP509031LNO
CSB-MP509031LNO
CSB-EP509031LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Aspartate 1-decarboxylase (panD) CSB-YP509032LNO
CSB-EP509032LNO
CSB-BP509032LNO
CSB-MP509032LNO
CSB-EP509032LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Elongation factor 4 (lepA), partial CSB-YP509033LNO
CSB-EP509033LNO
CSB-BP509033LNO
CSB-MP509033LNO
CSB-EP509033LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Potassium-transporting ATPase A chain (kdpA), partial CSB-YP509034LNO
CSB-EP509034LNO
CSB-BP509034LNO
CSB-MP509034LNO
CSB-EP509034LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Diaminopimelate epimerase (dapF) CSB-YP509035LNO
CSB-EP509035LNO
CSB-BP509035LNO
CSB-MP509035LNO
CSB-EP509035LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Ribosome maturation factor RimP (rimP) CSB-YP509036LNO
CSB-EP509036LNO
CSB-BP509036LNO
CSB-MP509036LNO
CSB-EP509036LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Periplasmic nitrate reductase (napA), partial CSB-YP509037LNO
CSB-EP509037LNO
CSB-BP509037LNO
CSB-MP509037LNO
CSB-EP509037LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Prolipoprotein diacylglyceryl transferase (lgt), partial CSB-YP509038LNO1
CSB-EP509038LNO1
CSB-BP509038LNO1
CSB-MP509038LNO1
CSB-EP509038LNO1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Sec-independent protein translocase protein TatA (tatA), partial CSB-YP509039LNO
CSB-EP509039LNO
CSB-BP509039LNO
CSB-MP509039LNO
CSB-EP509039LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis 30S ribosomal protein S10 (rpsJ) CSB-YP509040LNO
CSB-EP509040LNO
CSB-BP509040LNO
CSB-MP509040LNO
CSB-EP509040LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis 50S ribosomal protein L22 (rplV) CSB-YP509041LNO
CSB-EP509041LNO
CSB-BP509041LNO
CSB-MP509041LNO
CSB-EP509041LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis 30S ribosomal protein S5 (rpsE) CSB-YP509042LNO
CSB-EP509042LNO
CSB-BP509042LNO
CSB-MP509042LNO
CSB-EP509042LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis DNA-directed RNA polymerase subunit alpha (rpoA) CSB-YP509043LNO
CSB-EP509043LNO
CSB-BP509043LNO
CSB-MP509043LNO
CSB-EP509043LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Ribosomal RNA large subunit methyltransferase M (rlmM) CSB-YP509044LNO
CSB-EP509044LNO
CSB-BP509044LNO
CSB-MP509044LNO
CSB-EP509044LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis 50S ribosomal protein L25 (rplY) CSB-YP509045LNO
CSB-EP509045LNO
CSB-BP509045LNO
CSB-MP509045LNO
CSB-EP509045LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis tRNA (guanine-N (1)-)-methyltransferase CSB-YP509046LNO
CSB-EP509046LNO
CSB-BP509046LNO
CSB-MP509046LNO
CSB-EP509046LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis NAD-dependent deacetylase (cobB) CSB-YP509047LNO
CSB-EP509047LNO
CSB-BP509047LNO
CSB-MP509047LNO
CSB-EP509047LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis Uracil phosphoribosyltransferase (upp) CSB-YP509048LNO
CSB-EP509048LNO
CSB-BP509048LNO
CSB-MP509048LNO
CSB-EP509048LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Laribacter hongkongensis 50S ribosomal protein L32 (rpmF) CSB-YP509049LNO
CSB-EP509049LNO
CSB-BP509049LNO
CSB-MP509049LNO
CSB-EP509049LNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>